Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Core Viewpoint - Hoth Therapeutics has been granted a significant patent by the Japan Patent Office, enhancing its intellectual property portfolio in RNA-based cancer therapeutics, particularly targeting the KIT gene associated with various cancers [1][2][4]. Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative RNA-targeted precision therapies aimed at improving patient quality of life [5]. Patent Details - The newly issued patent covers antisense oligomers that target the KIT gene, which is linked to aggressive cancers such as gastrointestinal stromal tumors, leukemia, and mastocytosis [2][4]. - The patent includes antisense RNA molecules comprising 10–50 nucleotides, Morpholino and chemically modified antisense variants, as well as pharmaceutical compositions and expression vectors [7]. Strategic Importance - The patent strengthens Hoth's position in the RNA therapeutics market and supports its global strategy, providing validation and momentum for advancing its RNA platform towards clinical applications [3][4]. - Targeting the KIT pathway with antisense technology represents a precision-driven approach that could potentially overcome traditional small molecule resistance mechanisms [4][8]. Market Implications - The patent creates opportunities for licensing and partnerships in high-growth therapeutic areas, particularly in oncology, immunology, and rare diseases [8].